Superior Health-Related Quality of Life with Carfilzomib, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma (MM): Results From the ASPIRE Trial

e76 have had prior transplant (69.9% v 20.6%) v pts 70 yr. Median PFS for pts <70 yr was 28.6 months (95% confidence interval [CI], 24.1e32.3) for KRd v 17.6 months (95% CI, 14.5e22.2) for Rd (hazard ratio [HR], 0.668; P1⁄4.0002). Median PFS for pts 70 yr was 23.8 months (95% CI, 18.3e29.6) for KRd v 16.0 months (95% CI, 14.0e21.3) for Rd (HR, 0.739; P1⁄4.0521). Overall response rate for pts <70 yr was 86.0% for KRd v 66.9% for Rd (P<.0001), and was 90.3% (KRd) v 66.1% (Rd) for pts 70 yr (P<.0001). Among pts <70 yr, median treatment duration was 97.0 weeks (wk; range, 1.0e178.0) for KRd v 57.0 wk (range, 1.0e201.0) for Rd; among pts 70 yr, median treatment duration was 74.0 wk (range, 1.0e185.0) for KRd v 57.6 wk (range, 1.0e170.0) for Rd. Among pts<70 yr, the only grade 3 adverse event (AE) to occur 5.0% more frequently with KRd v Rd was hypophosphatemia (9.0% v 2.5%, respectively). Among pts 70 yr, the following grade 3 AEs were reported 5.0% more frequently with KRd v Rd: neutropenia (36.9% v 23.2%), thrombocytopenia (20.4% v 15.2%), and hypokalemia (15.5% v 6.3%). Conclusions: The use of KRd led to a 11-month improvement in median PFS v Rd in pts <70 yr and an 8-month improvement in median PFS in pts 70 yr. KRd had a favorable benefiterisk profile in pts with RMM aged <70 yr and 70 yr in the ASPIRE study. Editorial assistance was provided by BlueMomentum, an Ashfield Company, and supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary.